Inae Lim
Adult Health · Fort Lee, NJNPI 1033756010
Payments from drug & device makers
Across 802 payments — averaging $12.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$2K
- Novo Nordisk$1K
- Amgen$1K
- Lilly USA, LLC$1K
- Corcept Therapeutics$870
- Sanofi-aventis U.S. LLC$719
- plus $3K from 23 others
What the payments were for
- Food & beverage$9,67198%
- Education$541%
- Gifts$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 287 | $1,655 |
| Novo Nordisk | 134 | $1,489 |
| Amgen(2 entities) | 69 | $1,405 |
| Lilly USA, LLC | 111 | $1,065 |
| Corcept Therapeutics | 59 | $870 |
| Sanofi-aventis U.S. LLC | 28 | $719 |
| Bayer | 26 | $630 |
| Boehringer Ingelheim | 18 | $601 |
| Xeris Pharmaceuticals, Inc. | 17 | $250 |
| Medtronic | 8 | $204 |
| Cequr Corporation | 3 | $168 |
| AstraZeneca(2 entities) | 6 | $159 |
| Abbott | 5 | $95 |
| Ascendis Pharma Endocrinology Inc | 5 | $85 |
| Tolmar, Inc. | 5 | $77 |
| Dexcom, Inc. | 4 | $76 |
| Insulet Corporation | 3 | $72 |
| Amarin Pharma, Inc. | 2 | $42 |
| Pfizer | 2 | $29 |
| Astellas Pharma US Inc | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| EUSA Pharma (US) LLC | 1 | $17 |
| Radius Health, Inc. | 1 | $17 |
| Ascensia Diabetes Care US Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Intuity Medical Inc | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,844 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AfrezzaInsulin Regular, Human | 75 | $157,251 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 120 | $111,939 |
| OzempicSemaglutide | 77 | $109,254 |
| MounjaroTirzepatide | 64 | $87,790 |
| TrulicityDulaglutide | 68 | $86,350 |
| JardianceEmpagliflozin | 85 | $85,375 |
| FarxigaDapagliflozin Propanediol | 115 | $84,067 |
| Xigduo XrDapaglifloz Propaned/Metformin | 68 | $61,190 |
| Tresiba Flextouch U-100Insulin Degludec | 86 | $39,372 |
| TradjentaLinagliptin | 54 | $38,088 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 42 | $34,691 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 37 | $32,613 |
| JanuviaSitagliptin Phosphate | 31 | $24,650 |
| Jentadueto XrLinagliptin/Metformin Hcl | 32 | $22,477 |
| Cequr SimplicityBolus Insulin Pump, 200 Unit | 50 | $22,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta, Jentadueto Xr | $601 | $257,878291 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,065 | $177,120148 claims |
| Mannkind CorporationAfrezza | $1,655 | $157,25175 claims |
| Novo NordiskOzempic | $1,489 | $109,25477 claims |
| AstraZenecaFarxiga | $159 | $84,067115 claims |
| MerckJanuvia, Janumet Xr | $14 | $44,05549 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $719 | $32,61337 claims |
| Cequr CorporationCequr Simplicity | $168 | $22,11850 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.
Other adult health in Fort Lee
- June HalperHackensack$458K
- Kara SaggiomoCamden$127K
- Entela AhmetiPomona$75K
- Phyllis McKiernanHackensack$72K
- Denise ForceMiddletown$71K
- Kathleen SenecaHillsborough$64K
- Diane AndresenNorthvale$60K
- Dana BeenstockFreehold$51K
- Phyllis DudaCamden$46K
- Anthony WalkoWestwood$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.